Introduction: Various remineralizing agents can be used to remineralize initial carious lesions.Aim: The study aims to compare and evaluate the remineralizing efficiency of Remin Pro (VOCO GmbH, Cuxhaven, Germany), tricalcium phosphate, and HealOzone (CurOzone USA Inc., Ontario, Canada) by measuring the microhardness of enamel.Materials and method: Forty-five mandibular premolars were collected and divided into three groups (A, B, and C). After sectioning mesiodistally, they were subdivided into the control and test groups. The test group was further subdivided into demineralized (A 2a, B 2a, and C 2a ) and remineralized (A 2b, B 2b, and C 2b ) groups.All test group samples were demineralized by immersing in demineralizing solutions for 24 hours. Afterwards, A 2b, B 2b, and C 2b samples were remineralized by remineralizing agents (Remin Pro, tricalcium phosphate, and HealOzone) for three minutes (twice a day) for 14 days, and then Vickers microhardness testing (VHN) was performed.Result: The microhardness values of the demineralized group were lower compared to the samples of the control groups. In the remineralized group, the mean microhardness values were maximum for HealOzone (293.22 kgmm -2 ), followed by Remin Pro (287.5660 kgmm -2 ) and then tricalcium phosphate (282.4660 kgmm - 2). Conclusion:The application of remineralizing paste proved potent in improving the remineralization in the demineralized enamel surface.

No abstract

Fibromyalgia typically presents in young or middle-aged females as persistent widespread pain, stiffness, fatigue, disrupted unrefreshing sleep, and cognitive difculties, often accompanied by multiple other unexplained symptoms, anxiety and/or depression, and functional impairment of daily living activities. Management of Fibromyalgia at the present time is very difcult as it has multiple etiological factors and psychological predispositions; however, a patient centered approach is essential to handle this problem. Many adjunctive interventions have been implemented in bromyalgia treatment, but few are supported by controlled trials. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDAapproved for Fibromyalgia treatment, but many other agents have been tested over the years, with varying efcacy